Effects on host of modified PVP therapy combined with biological response modifiers in lung cancer.
- Authors:
- Published online on: January 1, 1998 https://doi.org/10.3892/or.5.1.103
- Pages: 103-110
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Abstract
We relieved several side effects by modifying chemotherapy and concurrently using biological response modifiers (BRMs) to experimentally and clinically investigate treatment, which can maintain quality of life (QOL) for lung cancer patients including changes in systemic immune capacity. sIL-2R levels are useful for predicting the course after recurrence. Immunosuppressive acid protein (IAP) levels are useful for detecting the presence or absence of recurrence and for predicting prognosis. BRMs are useful for continuing modified PVP (CDDP + VP-16) therapy, and sIL-2R and IAP levels for clarifying host conditions.